Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

Inclusion Criteria

• Age > 18 years - male or female

• Eligible female non-pregnant participants who are either not of child-bearing potential or willing to utilize adequate contraception during the trial
• Males must be willing to practice abstinence or utilize adequate contraception from MB-102 dosing day to at least 7 days post dose
• Participants willing to comply with study requirements
• Participants who have signed an informed consent form

At least 5 participants will have a current history of retinal or choroidal vascular diseases.

Exclusion Criteria

• Women who are pregnant, lactating or planning to become pregnant during the study, or women who are of childbearing potential unwilling to utilize adequate contraception
• Participation in another interventional trial within 30 days of treatment or concurrently enrolled in any other medical research study which could impact the results of the study
• History of drug or alcohol abuse within the past year
• History of severe allergic hypersensitivity reactions (unacceptable adverse events) or anaphylactoid reaction to any allergen including drugs, MB-102 and fluorescein sodium or other related products (intolerance to a drug is not considered a drug allergy).
• Prior history of seizures
• Current visually significant cataracts or other ophthalmic conditions that would limit appropriate collection of fundus photographs
• Site personnel immediately associated with the study or their immediate family members
• Unable to tolerate ophthalmologic imaging
• Any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial (e.g. unstable medical condition including cardiovascular disease, or other conditions considered clinically significant or unstable by the Principal Investigator)
• Prior enrollment and dosing in this study